Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2015	May 13, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	ALDX
Entity Registrant Name	ALDEYRA THERAPEUTICS, INC.
Entity Central Index Key	0001341235
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		9,590,021

Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 15,721,097	$ 8,527,304
Prepaid expenses and other current assets	177,074	232,568
Total current assets	15,898,171	8,759,872
Deferred offering costs	20,000	14,238
Fixed assets, net	13,182	12,993
Total assets	15,931,353	8,787,103
Current liabilities:
Accounts payable	406,145	341,294
Accrued expenses	436,157	908,724
Current portion of credit facility	193,866	77,546
Total current liabilities	1,036,168	1,327,564
Credit facility, net of current portion and debt discount	1,068,515	1,175,481
Total liabilities	2,104,683	2,503,045
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding as of March 31, 2015 and December 31, 2014
Common stock, voting, $0.001 par value; 150,000,000 authorized and 6,890,021 shares issued and outstanding as of March 31, 2015 and 5,565,415 shares issued and outstanding as of December 31, 2014	6,890	5,565
Additional paid-in capital	62,467,936	52,790,090
Accumulated deficit	(48,648,156)	(46,511,597)
Total stockholders' equity	13,826,670	6,284,058
Total liabilities and stockholders' equity	$ 15,931,353	$ 8,787,103

Balance Sheets (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	15,000,000	15,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	6,890,021	6,890,021
Common stock, shares outstanding	6,890,021	6,890,021

Statements of Operations and Comprehensive Income (Loss) (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating expenses:
Research and development	$ 1,136,434	$ 444,278
General and administrative	972,101	800,646
Loss from operations	(2,108,535)	(1,244,924)
Other income (expense):
Change in fair value of preferred stock warrant liabilities		1,759,915
Interest income		3
Interest expense	(28,024)	(113,221)
Total other income, net	(28,024)	1,646,697
Net (loss) income and comprehensive (loss) income	(2,136,559)	401,773
Accretion of preferred stock		(191,568)
Allocation of undistributed earnings to preferred stockholders		(223,442)
Net loss attributable to common stockholders	$ (2,136,559)	$ (13,237)
Net loss per share attributable to common stockholders:
Basic	$ (0.32)	$ (0.04)
Diluted	$ (0.32)	$ (4.04)
Weighted average common shares outstanding:
Basic	6,667,519	327,365
Diluted	6,667,519	438,975

Statements of Stockholders' Equity (Unaudited) (USD $)	Total	Common Voting Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2014	$ 6,284,058	$ 5,565	$ 52,790,090	$ (46,511,597)
Beginning Balance, Shares at Dec. 31, 2014		5,565,415
Stock-based compensation	640,073		640,073
Issuance of common stock, net of issuance costs	9,039,098	1,325	9,037,773
Issuance of common stock, net of issuance costs, Shares		1,324,606
Net loss	(2,136,559)			(2,136,559)
Ending Balance at Mar. 31, 2015	$ 13,826,670	$ 6,890	$ 62,467,936	$ (48,648,156)
Ending Balance, Shares at Mar. 31, 2015		6,890,021

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References+ Details

Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
Statements of Cash Flows (Unaudited) (USD $)	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ (2,136,559)	$ 401,773
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Stock-based compensation	640,073	365,686
Amortization of debt discount - non-cash interest expense	9,354	87,980
Change in fair value of warrant liability, purchase rights and warrant purchase rights		(1,759,915)
Depreciation	1,252
Change in operating assets and liabilities: (Increase) decrease
Prepaid expenses and other current assets	55,494	(1,329)
Accounts payable	64,851	(175,892)
Accrued interest on convertible notes related parties		2,607
Accrued expenses	(478,329)	15,198
Net cash used in operating activities	(1,843,864)	(1,063,892)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisitions of property and equipment	(1,441)
Net cash used in investing activities	(1,441)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of issuance costs	9,039,098
Cash paid for deferred offering costs		(52,841)
Net cash provided by (used in) financing activities	9,039,098	(52,841)
NET INCREASE IN CASH	7,193,793	(1,116,733)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	8,527,304	3,262,354
CASH AND CASH EQUIVALENTS, END OF PERIOD	15,721,097	2,145,621
Cash paid during the period for:
Interest	18,320	22,682
SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Accretion of redeemable convertible preferred stock		191,568
Deferred offering costs not yet paid	$ 20,000	$ 209,896

Nature of Business

3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

Nature of Business

1.	NATURE OF BUSINESS

Aldeyra Therapeutics, Inc. (the Company or Aldeyra) was incorporated in the state of Delaware. The Company is developing a treatment for diseases thought to be related to high levels of free aldehydes, naturally occurring pro-inflammatory toxins.

The Company’s principal activities to date include raising capital and research and development activities.

Basis of Presentation

3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

Basis of Presentation

2.	BASIS OF PRESENTATION

The accompanying interim unaudited condensed financial statements and related disclosures are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s financial statements and related footnotes for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10 -K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission on March 23, 2015. The financial information as of March 31, 2015, the three months ended March 31, 2015 and 2014 is unaudited, but in the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation of the financial position, results of operations and cash flows at the dates and for the periods presented of the results of these interim periods have been included. The balance sheet data as of December 31, 2014 was derived from audited financial statements. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.

On January 14, 2015, the Company sold, in a private placement, an aggregate of approximately 1.1 million shares of common stock at a price of $7.00 per share. Investors received warrants to purchase up to approximately 1.1 million shares of common stock at an exercise price of $9.50. The warrants will expire 3 years from the date of issuance. The warrants do not include a net-exercise feature. The warrants may be redeemed by the Company at a price of $0.001 per share upon notice to the holders in the event that the closing bid for Aldeyra’s common stock for each of the fifteen consecutive trading days prior to such redemption is at least $20.00 per share and the average trading volume of Aldeyra’s common stock during such period is 50,000 shares per day. Following Aldeyra’s notification to the warrant holders of its exercise of the redemption right under the warrants, each warrant holder will have the option to exercise their warrants prior to the redemption date rather than having them redeemed. The Company raised approximately $7.1 million in net proceeds in the private placement of common stock and warrants.

On January 21, 2015, in a subsequent private placement, the Company sold an aggregate of 211,528 shares of common stock at a price of $9.33 per share and a warrant to purchase up to 211,528 shares of common stock at a price of $0.125 per share subject to the warrant. The exercise price of the warrant is $9.50 per share. The warrant will expire 3 years from the date of issuance. The warrant does not include a net-exercise feature. The warrant may be redeemed by the Company at a price of $0.001 per share upon notice to the holder thereof in the event that the closing bid for Aldeyra’s common stock for each of the fifteen consecutive trading days prior to such redemption is at least $20.00 per share and the average trading volume of Aldeyra’s common stock during such period is at least 50,000 shares per day. Following Aldeyra’s notification to the warrant holder of its exercise of the redemption right under the warrant, the warrant holder will have the option to exercise the warrant prior to the redemption date rather than having it redeemed. The Company raised approximately $2.0 million in net proceeds in the private placement of common stock and a warrant to purchase common stock.

In addition, the Company raised $18.8 million, after deducting underwriting discounts and commissions and other offering expenses, on May 13, 2015, through the issuance and sale of 2,700,000 shares of common stock in a follow-on public offering.

The Company’s management believes that its currently available resources, including funds obtained from the May 2015 follow-on public offering and amounts potentially available under its credit facility Note 5, will provide sufficient funds to enable the Company to meet its expected obligations through approximately the end of 2017 based on the Company’s current business plan. However, these amounts will not be sufficient for the Company to commercialize its product candidates or conduct any substantial, additional development requirements requested by the FDA. Additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to secure additional capital, or meet financial covenants that could be implemented under the Company’s term loans in certain circumstances, it will be required to significantly decrease the amount of planned expenditures, and may be required to cease operations.

Curtailment of operations would cause significant delays in the Company’s efforts to introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company.

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Net Loss Attributable to Common Stockholders

3 Months Ended

Mar. 31, 2015

Earnings Per Share [Abstract]

Net Loss Attributable to Common Stockholders

3.	NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

Net loss attributable to common stockholders

The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:


	Three Months Ended March 31,
	2015			2014
Numerator:
Basic
Net (loss) income and comprehensive (loss) income	$	(2,136,559	)	$	401,773
Accretion of preferred stock		—			(191,568	)
Allocation of undistributed earnings to preferred stockholders		—			(223,442	)

Net loss attributable to common stockholders – basic	$	(2,136,559	)	$	(13,237	)

Diluted
Net loss attributable to common stockholders – basic		(2,136,559	)		(13,237	)
Less: change in fair value of derivative liabilities		—			(1,759,915	)

Net loss available to common stockholders – diluted	$	(2,136,559	)	$	(1,773,152	)

Denominator:
Basic
Weighted-average number of common shares – basic		6,667,519			327,365

Diluted
Weighted-average number of common shares – basic		6,667,519			327,365
Warrants to purchase preferred stock (treasury stock)		—			111,610

Total weighted average number of common shares – diluted		6,667,519			438,975

Net loss per share:
Basic	$	(0.32	)	$	(0.04	)
Diluted	$	(0.32	)	$	(4.04	)

The following potentially dilutive securities outstanding, prior to use of the treasury stock method or if-converted method, have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact:


	Three Months ended March 31,
	2015		2014

Options to purchase common stock		874,032		609,842
Preferred Stock		—		303,567
Convertible note payable-related parties		—		3,810
Warrants to purchase common stock		1,384,608		—

Total of common stock equivalents		2,258,640		917,219

For the three months ended March 31, 2014, the Company corrected on a prospective basis its calculation of weighted average common shares on a diluted basis from what the Company had disclosed previously for the same period. The prospective modification reflects a change to the Stock options (treasury stock) from 4,851 shares to no shares which also resulted in a change to the diluted net loss per share from ($4.00) to ($4.04).

- Definition

The entire disclosure for earnings per share.

+ References+ Details

Fair Value Measurements

3 Months Ended

Mar. 31, 2015

Fair Value Disclosures [Abstract]

Fair Value Measurements

4.	FAIR VALUE MEASUREMENTS

As of March 31, 2015 and December 31, 2014, the carrying amounts of cash and cash equivalents, prepaid expenses and other current assets, and accounts payable approximated their estimated fair values because of the short term nature of these financial instruments. The carrying value of the Company’s credit facility in current and long-term liabilities approximates fair value because the Company’s interest rate yield is near current market rates available to the Company.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value are performed in a manner to maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820, Fair Value Measurements, establishes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:

Level 1 – Quoted prices in active markets that are accessible at the market date for identical unrestricted assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

There were no assets or liabilities measured at fair value at March 31, 2015 or December 31, 2014.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References+ Details

Credit Facility

3 Months Ended

Mar. 31, 2015

Debt Disclosure [Abstract]

Credit Facility

5.	CREDIT FACILITY

In April 2012, the Company entered into a loan and security agreement (the Credit Facility) with Square 1 Bank (Square 1) which was amended in November 2013, November 2014 and March 18, 2015. Pursuant to the amended Credit Facility, Square 1 agreed to make term loans in a principal amount of up to $5,000,000 available to the Company with proceeds to be used first to refinance outstanding loans from Square 1, second to fund expenses related to the Company’s clinical trials, and the remainder for general working capital purposes. The term loans are to be made available to the Company upon the following terms: (i) $2,000,000 was made available in November 2014; and (ii) $3,000,000 (the Tranche B Loan) is to be made available to the Company following the satisfaction of certain conditions, including receipt of positive phase 2 data in either Sjögren-Larsson Syndrome (SLS) or noninfectious anterior uveitis. As of March 31, 2015, $1,395,833 was outstanding under the Credit Facility. Each term loan accrues interest from its date of issue at a variable annual interest rate equal to the greater of 2.0% plus prime or 5.25% per annum. Any term loan made is payable as interest-only prior to November 2015 and thereafter is payable in monthly installments of principal plus accrued interest over 36 months. The Credit Facility is collateralized by the Company’s assets, including its intellectual property.

At March 31, 2015, the Credit Facility is shown net of a remaining debt discount of $133,453 which is being amortized using the effective interest method through the current maturity date of the Credit Facility, November 2018.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details

Income Taxes

3 Months Ended

Mar. 31, 2015

Income Tax Disclosure [Abstract]

Income Taxes

6.	INCOME TAXES

No provision for federal taxes has been recorded as the Company has incurred losses since inception for tax purposes. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

In assessing the realizability of net deferred taxes in accordance with ASC 740, Income Taxes, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Based on the weight of available evidence, primarily the incurrence of net losses since inception and anticipated net losses in the near future, the Company does not consider it more likely than not that some or all of the net deferred taxes will be realized. Accordingly, a 100% valuation allowance has been applied against net deferred taxes.

Under the provisions of the Internal Revenue Code, certain substantial changes in the Company’s ownership may result in a limitation on the amount of net operating loss carryforwards which can be used in future years.

All tax years are open for examination by the taxing authorities for both federal and state purposes.

The Company accounts for uncertain tax positions pursuant to ASC 740 which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes. Management is not aware of any uncertain tax positions.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

Stock Incentive Plan

3 Months Ended

Mar. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Incentive Plan

7.	STOCK INCENTIVE PLAN

The Company has three incentive plans. One was adopted in 2004 (2004 Plan) and provided for the granting of stock options and restricted stock awards and generally prescribed a contractual term of seven years. The 2004 Plan terminated in August 2010. However, grants made under the 2004 Plan are still governed by that plan. As of March 31, 2015, options to purchase 23,954 shares of common stock at an exercise price of $3.24 per share remained outstanding under the 2004 Plan.

The Company approved the 2010 Employee, Director and Consultant Equity Incentive Plan (2010 Plan) in September 2010 to replace the 2004 Plan. The 2010 Plan provided for the granting of stock options and restricted stock awards. The 2010 Plan terminated upon the Initial Public Offering. However, grants made under the 2010 Plan are still governed by that plan. As of March 31, 2015, options to purchase 585,888 shares of common stock at a weighted average exercise price of $1.41 per share remained outstanding under the 2010 Plan.

The Company approved the 2013 Equity Incentive Plan (2013 Plan) in October 2013. The 2013 Plan became effective immediately on adoption although no awards were to be made under it until the effective date of the Registration Statement for the Initial Public Offering. The 2013 Plan provides for the granting of stock options, restricted stock, stock appreciation rights, stock units, and performance cash awards to certain employees, members of the board of directors and consultants of the Company. As of December 31, 2014, the number of shares of common stock authorized for issuance in connection with the 2013 Plan was 625,000. On January 1 of each year the aggregate number of common shares that may be issued under the Plan shall automatically increase by a number equal to the least of (a) 4% of the total number of common shares outstanding on the last calendar day of the prior fiscal year, (b) subject to adjustment for certain corporate transactions, 333,333 common shares, or (c) a number of common shares determined by the Company’s board of directors. As of January 1, 2015, the number of shares of common stock that may be issued under the 2013 Plan was automatically increased by 222,617 shares, increasing the number of shares of common stock available for issuance under the 2013 Plan to 847,617 shares. As of March 31, 2015, options to purchase 264,190 shares of common stock at a weighted average exercise price of $6.84 per share remained outstanding under the 2013 Plan.

Terms of stock award agreements, including vesting requirements, are determined by the Company’s board of directors or its compensation committee, subject to the provisions of the respective plan they were granted. Options granted by the Company typically vest over a four year period. Certain of the options are subject to acceleration of vesting in the event of certain change of control transactions. The options may be granted for a term of up to ten years from the date of grant. The exercise price for options granted under the 2013 Plan must be at a price no less than 100% of the fair market value of a common share on the date of grant. As of March 31, 2015, the number of shares of common stock authorized for issuance in connection with the Company’s three stock incentive plans was 871,571.

The following table summarizes information about stock options exercisable at March 31, 2015:

Period Ending

Number
Exercisable

Outstanding
Options
Weighted-
Average
Remaining
Contractual
Life

Exercisable
Options
Weighted-
Average
Remaining
Contractual
Life

March 31, 2015

239,369

8.49

7.77

During the year ended December 31, 2013, the Company granted two options exercisable for a total of 32,014 common shares for which vesting is contingent on certain performance and market-based conditions. For options granted containing performance conditions, the fair value is determined on the date of grant. For the three months ended March 31, 2015, there was $200,376 expense recorded relating to the options granted in 2013 as the market-based conditions were satisfied in January 2015 and the shares vested. No stock options were granted, exercised, forfeited or cancelled during the three months ended March 31, 2015. The total aggregate intrinsic value of stock options outstanding and exercisable as of March 31, 2015 was $419,000.

Stock-based compensation is recognized for stock options granted to employees and non-employees and has been reported in the Company’s statement of operations as follows:


	March 31,
	2015		2014

Research and development expenses	$	298,714	$	78,526
General and administrative expenses		341,359		287,160

Total stock-based compensation expense	$	640,073	$	365,686

As of March 31, 2015 unamortized stock based compensation was $3,863,472 and will be recognized over a weighted average period of 4.81 years.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

Stock Purchase Warrants

3 Months Ended

Mar. 31, 2015

Text Block [Abstract]

Stock Purchase Warrants

8.	STOCK PURCHASE WARRANTS

In connection with the Initial Public Offering, the Company issued the underwriters of the offering warrants to purchase up to 60,000 shares of common stock. The warrants are exercisable beginning on May 1, 2015 for cash or on a cashless basis at a per share price of $10.00. The warrants will expire on May 1, 2019 were outstanding at March 31, 2015.

Commitments and Contingencies

3 Months Ended

Mar. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

9.	COMMITMENTS AND CONTINGENCIES

In the ordinary course of its business, the Company may be involved in various legal proceedings involving contractual and employment relationships, trademark rights, and a variety of other matters. The Company is not aware of any pending legal proceedings that will have a material impact on the Company’s financial position or results of operations.

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

Subsequent Events

3 Months Ended

Mar. 31, 2015

Subsequent Events [Abstract]

Subsequent Events

10.

SUBSEQUENT EVENTS

On May 13, 2015, the Company issued and sold a total of 2,700,000 shares of its common stock at $7.50 per share in an underwritten public offering. Net proceeds from the offering was approximately $18.8 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Basis of Presentation (Policies)	3 Months Ended
Basis of Presentation (Policies)	Mar. 31, 2015
Accounting Policies [Abstract]
Use of Estimates	*Use of estimates* The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Net Loss Attributable to Common Stockholders (Tables)

3 Months Ended

Mar. 31, 2015

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders

The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:


	Three Months Ended March 31,
	2015			2014
Numerator:
Basic
Net (loss) income and comprehensive (loss) income	$	(2,136,559	)	$	401,773
Accretion of preferred stock		—			(191,568	)
Allocation of undistributed earnings to preferred stockholders		—			(223,442	)

Net loss attributable to common stockholders – basic	$	(2,136,559	)	$	(13,237	)

Diluted
Net loss attributable to common stockholders – basic		(2,136,559	)		(13,237	)
Less: change in fair value of derivative liabilities		—			(1,759,915	)

Net loss available to common stockholders – diluted	$	(2,136,559	)	$	(1,773,152	)

Denominator:
Basic
Weighted-average number of common shares – basic		6,667,519			327,365

Diluted
Weighted-average number of common shares – basic		6,667,519			327,365
Warrants to purchase preferred stock (treasury stock)		—			111,610

Total weighted average number of common shares – diluted		6,667,519			438,975

Net loss per share:
Basic	$	(0.32	)	$	(0.04	)
Diluted	$	(0.32	)	$	(4.04	)

Computation of Diluted Weighted-Average Shares Outstanding


	Three Months ended March 31,
	2015		2014

Options to purchase common stock		874,032		609,842
Preferred Stock		—		303,567
Convertible note payable-related parties		—		3,810
Warrants to purchase common stock		1,384,608		—

Total of common stock equivalents		2,258,640		917,219

Stock Incentive Plan (Tables)

3 Months Ended

Mar. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Stock Options Exercisable

The following table summarizes information about stock options exercisable at March 31, 2015:

Period Ending

Number
Exercisable

Outstanding
Options
Weighted-
Average
Remaining
Contractual
Life

Exercisable
Options
Weighted-
Average
Remaining
Contractual
Life

March 31, 2015

239,369

8.49

7.77

Schedule of Stock-Based Compensation Expense

Stock-based compensation is recognized for stock options granted to employees and non-employees and has been reported in the Company’s statement of operations as follows:


	March 31,
	2015		2014

Research and development expenses	$	298,714	$	78,526
General and administrative expenses		341,359		287,160

Total stock-based compensation expense	$	640,073	$	365,686

Basis of Presentation - Additional Information (Detail) (USD $) In Millions, except Share data, unless otherwise specified	0 Months Ended				0 Months Ended
	Jan. 21, 2015	Jan. 14, 2015	Jan. 21, 2015	Jan. 14, 2015	May 13, 2015 Subsequent Event [Member]	May 13, 2015 Subsequent Event [Member]
Class of Stock [Line Items]
Common stock shares sold	211,528	1,100,000			2,700,000
Common stock issued price per share			$ 9.33	$ 7.00		$ 7.50
Common stock purchased			211,528	1,100,000
Common stock exercise price			$ 0.125	$ 9.50
Warrant expiration date	3 years	3 years
Warrant redemption price	$ 0.001	$ 0.001
Share price of common stock			$ 20.00	$ 20.00
Trading volume of common stock	50,000	50,000
Private placement of common stock and warrants raised	$ 2.0	$ 7.1
Exercise price of warrant	$ 9.50
Proceeds from initial public offering net of underwriting discounts, commissions and offering costs					$ 18.8

Net Loss Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Basic
Net (loss) income and comprehensive (loss) income	$ (2,136,559)	$ 401,773
Accretion of preferred stock		(191,568)
Allocation of undistributed earnings to preferred stockholders		(223,442)
Net loss attributable to common stockholders - basic	(2,136,559)	(13,237)
Diluted
Net loss attributable to common stockholders - basic	(2,136,559)	(13,237)
Less: change in fair value of derivative liabilities		(1,759,915)
Net loss available to common stockholders - diluted	$ (2,136,559)	$ (1,773,152)
Basic
Weighted-average number of common shares - basic	6,667,519	327,365
Diluted
Weighted-average number of common shares - basic	6,667,519	327,365
Warrants to purchase preferred stock (treasury stock)		111,610
Total weighted average number of common shares - diluted	6,667,519	438,975
Net loss per share:
Basic	$ (0.32)	$ (0.04)
Diluted	$ (0.32)	$ (4.04)

Net Loss Attributable to Common Stockholders - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Net Income Loss Per Common Share [Line Items]
Stock options (treasury stock)		0
Dilute net loss per share	$ (0.32)	$ (4.04)
Scenario, Previously Reported [Member]
Net Income Loss Per Common Share [Line Items]
Stock options (treasury stock)		4,851
Dilute net loss per share		$ (4.00)

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References+ Details

Net Loss Attributable to Common Stockholders - Computation of Diluted Weighted-Average Shares Outstanding (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of common stock equivalents	2,258,640	917,219
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of common stock equivalents		303,567
Common Voting Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of common stock equivalents	1,384,608
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of common stock equivalents	874,032	609,842
Convertible Note Payable-Related Parties [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of common stock equivalents		3,810

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

Fair Value Measurements - Additional Information (Detail) (USD $)	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Liabilities measured at fair value on a recurring basis	$ 0
Assets measured at fair value on a recurring basis	$ 0

Credit Facility - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Line of Credit Facility [Line Items]
Net of debt discount amount	$ 133,453
Line of credit facility maturity date	2018-11
Square One Bank [Member]
Line of Credit Facility [Line Items]
Credit facility amount	1,395,833
Proceeds from credit facility	2,000,000
Debt instrument annual interest rate	5.25%
Loan repayment period	36 months
Square One Bank [Member] \| Prime Rate [Member]
Line of Credit Facility [Line Items]
Debt instrument variable annual interest rate	2.00%
Square One Bank [Member] \| Term Loan [Member]
Line of Credit Facility [Line Items]
Credit facility amount	5,000,000
Square One Bank [Member] \| Tranche B Loans [Member]
Line of Credit Facility [Line Items]
Proceeds from credit facility	$ 3,000,000

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References+ Details

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Provision for income tax benefit	$ 0
Deferred tax assets valuation allowance	100.00%

Stock Incentive Plan - Additional Information (Detail) (USD $)	3 Months Ended			0 Months Ended	3 Months Ended			3 Months Ended
	Mar. 31, 2015 Plan Incentive_Plan	Mar. 31, 2015 2004 Plan [Member]	Mar. 31, 2015 2010 Plan [Member]	Jan. 01, 2015 2013 Plan [Member]	Mar. 31, 2015 2013 Plan [Member]	Jan. 01, 2015 2013 Plan [Member]	Dec. 31, 2014 2013 Plan [Member]	Mar. 31, 2015 Two Grants [Member]	Dec. 31, 2013 Two Grants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of incentive plans	3
Stock incentive plans, contractual term		Seven years
Stock incentive plan, termination date		August 2010
Options to purchase of shares of common stock		23,954	585,888		264,190
Exercise price per share of common stock		$ 3.24	$ 1.41		$ 6.84
Issuance of common stock authorized							625,000
Percentage of increase in common shares outstanding					4.00%
Increase in common stock outstanding					$ 333,333
Common stock issued under 2013 plan				222,617
Common stock available for issuance						847,617
Stock option granted in term years	10 years
Fair value of a common stock percentage	100.00%
Number of stock incentive plans	3
Number of shares of common stock authorized for issuance	871,571
Options exercisable	239,369								32,014
Expense relating to options								200,376
Stock options granted								0
Stock options exercised								0
Stock options forfeited or cancelled								0
Aggregate intrinsic value of stock options outstanding and exercisable								$ 419,000
Unrecognized compensation cost	$ 3,863,472
Weighted average period	4 years 9 months 22 days

Stock Incentive Plan - Summary of Stock Options Exercisable (Detail)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number Exercisable	239,369
Outstanding Options Weighted-Average Remaining Contractual Life	8 years 10 months 24 days
Exercisable Options Weighted-Average Remaining Contractual Life	7 years 9 months 7 days

Stock Incentive Plan - Schedule of Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 640,073	$ 365,686
Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	298,714	78,526
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 341,359	$ 287,160

Stock Purchase Warrants - Additional Information (Detail) (USD $)	0 Months Ended				3 Months Ended
	Jan. 21, 2015	Jan. 14, 2015	Jan. 21, 2015	Jan. 14, 2015	Mar. 31, 2015 Warrant [Member]
Class of Warrant or Right [Line Items]
Common stock shares sold	211,528	1,100,000
Common stock issued price per share			$ 9.33	$ 7.00
Warrant to purchase Common stock exercise price			211,528	1,100,000	60,000
Exercise price of warrant			$ 0.125	$ 9.50	$ 10
Warrant expiration date	3 years	3 years
Warrant redemption price	$ 0.001	$ 0.001
Share price of common stock			$ 20.00	$ 20.00
Trading volume of common stock	50,000	50,000
Exercise price of warrant	$ 9.50
Warrants exercisable date					May 01, 2015
Warrants expiration date					May 01, 2019

Subsequent Event - Additional Information (Detail) (USD $) In Millions, except Share data, unless otherwise specified	0 Months Ended				0 Months Ended
	Jan. 21, 2015	Jan. 14, 2015	Jan. 21, 2015	Jan. 14, 2015	May 13, 2015 Subsequent Event [Member]	May 13, 2015 Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock shares sold	211,528	1,100,000			2,700,000
Common stock issued price per share			$ 9.33	$ 7.00		$ 7.50
Proceeds from initial public offering net of underwriting discounts, commissions and offering costs					$ 18.8